Inflammatory Bowel Disease | Pipeline Drugs update.
'Companies target high unmet need in anti-TNF-failure patient populations'
By Joseph Hedden, Senior Analyst
21 August 2013
I am an analyst at Datamonitor Healthcare, having previously completed a PhD in Structural and Molecular Biology at Univ...
Read full bio
Pharmaceutical companies could draw significant commercial reward if they can get their drugs indicated for the treatment of patients who have failed or become intolerant to anti-tumor necrosis factor (anti-TNF) biologics.
This opportunity has been created by high unmet need due to limited treatment options for ulcerative colitis patients who have failed anti-TNF therapy, and the poor efficacy of existing approved drugs Humira and Tysabri in Crohn’s disease patients who have failed anti-TNF therapy. Pfizer will position Xeljanz as a therapy for ulcerative colitis anti-TNF-failure patients, and Johnson & Johnson is set to position Stelara as a therapy for Crohn’s disease anti-TNF-failure patients.
Comprehensive analysis of products in Phase III development for the treatment of Crohn’s disease and ulcerative colitis across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK), including a detailed review of clinical trial design.
Competition in the Crohn’s disease and ulcerative colitis markets is set to intensify as a wave of new drugs will gain regulatory approvals in the next few years. Targeting anti-TNF-failure patient populations could prove lucrative for companies, providing their drugs are effective here.
Phase III data suggest vedolizumab can compete with Remicade in the Crohn’s disease and ulcerative colitis markets. The continued evolution of clinical trial design will allow companies to better distinguish their drug candidates from marketed therapies.
Datamonitor Healthcare has analyzed Phase III candidates in Crohn’s disease and ulcerative colitis pipelines using a variety of sources, including Citeline, Medtrack, Sagient BioMedTracker, and company websites. Pipeline and existing therapies have been benchmarked against Datamonitor Healthcare’s choice of comparator (Remicade), with key opinion leader input.
This is an Immunology and Inflammation analysis update from the Datamonitor Healthcare service, which provides regular and event-senstive research for key drugs and companies, treatment trends, patient populations and strategic issues.
- For more information on this research, please contact
- For current clients, please log-in to view the full analysis at: